GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn ...

Vaccines used were the monovalent vaccines Engerix B and GenHBvax (Merck, West Point, PA), the hexavalent preparations Infanrix hexa (GlaxoSmithKline Biologicals) and Hexavac (Sanofi Pasteur ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

GlaxoSmithKline Pharmaceuticals Limited ... The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix.

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over its old heartburn drug Zantac, an issue that has weighed on the ...

The GSK share price has had a rotten few years and now it’s heading south yet again. Investor Harvey Jones continues to hang on in the hope that it will recover. When investing, your capital is ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before litigation started in summer 2022. The drugs group rose 5% or 77.5p to 1535 ...